Merck & Co [MRK] vs Amgen [AMGN] Detailed Stock Comparison

Merck & Co., Inc.

NYSE
Loading...

Amgen Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Merck & Co., Inc. wins in 15 metrics, Amgen Inc. wins in 6 metrics, with 0 ties. Merck & Co., Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Merck & Co., Inc. Amgen Inc. Better
P/E Ratio (TTM) 15.74 24.22 Merck & Co., Inc.
Price-to-Book Ratio 5.39 21.46 Merck & Co., Inc.
Debt-to-Equity Ratio 95.96 640.28 Merck & Co., Inc.
PEG Ratio -0.82 0.22 Amgen Inc.
EV/EBITDA 10.97 13.97 Merck & Co., Inc.
Profit Margin (TTM) 28.08% 20.98% Merck & Co., Inc.
Operating Margin (TTM) 32.77% 30.55% Merck & Co., Inc.
EBITDA Margin (TTM) 32.77% 30.55% Merck & Co., Inc.
Return on Equity 36.88% 106.10% Amgen Inc.
Return on Assets (TTM) 12.04% 7.93% Merck & Co., Inc.
Free Cash Flow (TTM) $12.36B $8.10B Merck & Co., Inc.
Dividend Yield 2.91% 3.30% Amgen Inc.
1-Year Return 45.70% 20.32% Merck & Co., Inc.
Price-to-Sales Ratio (TTM) 4.35 5.06 Merck & Co., Inc.
Enterprise Value $319.41B $232.21B Merck & Co., Inc.
EV/Revenue Ratio 4.91 6.32 Merck & Co., Inc.
Gross Profit Margin (TTM) 66.15% 69.84% Amgen Inc.
Revenue per Share (TTM) $26 $68 Amgen Inc.
Earnings per Share (Diluted) $7.28 $14.24 Amgen Inc.
Beta (Stock Volatility) 0.28 0.47 Merck & Co., Inc.
Short % of Float 1.12% 2.60% Merck & Co., Inc.

Merck & Co., Inc. vs Amgen Inc. Stock Performance Analysis

Loading Price Chart...

MRK
AMGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Merck & Co., Inc.-3.49%-3.87%3.16%-0.46%14.60%7.94%
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Merck & Co., Inc.45.70%8.90%55.40%123.23%252.74%262.85%
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%

Performance & Financial Health Analysis: Merck & Co., Inc. vs Amgen Inc.

MetricMRKAMGN
Market Information
Market Cap i$283.10B$187.93B
Market Cap CategoryMega capLarge cap
10 Day Avg. Volume i9,732,9982,431,753
90 Day Avg. Volume i9,710,0492,596,291
Last Close$114.90$350.53
52 Week Range$76.66 - $125.14$267.83 - $391.29
% from 52W High-8.18%-10.42%
All-Time High$134.63 (Jun 24, 2024)$391.29 (Mar 02, 2026)
% from All-Time High-14.65%-10.42%
Growth Metrics
Quarterly Revenue Growth0.05%0.09%
Quarterly Earnings Growth-0.21%1.13%
Financial Health
Profit Margin (TTM) i0.28%0.21%
Operating Margin (TTM) i0.33%0.31%
Return on Equity (TTM) i0.37%1.06%
Debt to Equity (MRQ) i95.96640.28
Cash & Liquidity
Book Value per Share (MRQ)$21.26$16.07
Cash per Share (MRQ)$5.89$16.94
Operating Cash Flow (TTM) i$16.47B$9.96B
Levered Free Cash Flow (TTM) i$11.89B$7.50B
Dividends
Last 12-Month Dividend Yield i2.91%3.30%
Last 12-Month Dividend i$3.32$12.18

Valuation & Enterprise Metrics Analysis: Merck & Co., Inc. vs Amgen Inc.

MetricMRK (Apr 24, 2026)AMGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i15.7424.22
Forward P/E i11.8014.77
PEG Ratio i-0.820.22
Price to Sales (TTM) i4.355.06
Price to Book (MRQ) i5.3921.46
Market Capitalization
Market Capitalization i$283.10B$187.93B
Enterprise Value i$319.41B$232.21B
Enterprise Value Metrics
Enterprise to Revenue i4.916.32
Enterprise to EBITDA i10.9713.97
Risk & Other Metrics
Beta i0.280.47
Book Value per Share (MRQ) i$21.26$16.07

Financial Statements Comparison: Merck & Co., Inc. vs Amgen Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMRK (2025)AMGN (2025)
Revenue/Sales i65.01B36.75B
Cost of Goods Sold i16.38B12.04B
COGS % of Revenue i25.2%32.8%
Gross Profit i48.63B24.71B
Gross Margin i74.8%67.2%
Research & Development i15.79B7.27B
Operating Income (EBIT) i22.11B9.08B
Operating Margin i34.0%24.7%
EBITDA i29.11B16.90B
EBITDA Margin i44.8%46.0%
Pre-Tax Income i21.07B8.98B
Pre-Tax Income % of Revenue i32.4%24.4%
Income Tax i2.80B1.27B
Income Tax % of Revenue i4.3%3.4%
Net Income (Profit) i18.26B7.71B
Profit Margin i28.1%21.0%

Balance Sheet & Liquidity Metrics

MetricMRK (2025)AMGN (2025)
Cash & Equivalents i14.57B9.13B
Total Current Assets i43.52B29.06B
Total Current Assets % of Revenue i66.9%79.1%
Total Current Liabilities i28.33B25.49B
Total Current Liabilities % of Revenue i43.6%69.4%
Long-Term Debt i46.75B50.01B
Long-Term Debt % of Revenue i71.9%136.1%
Total Shareholders Equity i52.66B8.66B
Retained Earnings i73.08B-25.11B
Retained Earnings % of Revenue i112.4%-68.3%
Property, Plant & Equipment i05.22B

Cash Flow Statement Comparison

MetricMRK (2025)AMGN (2025)
Operating Cash Flow i18.49B10.51B
Operating Cash Flow % of Revenue i28.4%28.6%
Capital Expenditures iN/A-1.86B
Free Cash Flow i12.36B8.10B
FCF Margin i19.0%22.0%
Debt Repayment i-2.50B-5.00B
Common Stock Repurchase i-5.08B0

Short Interest & Institutional Ownership Analysis

MetricMRKAMGN
Shares Short i27.72M13.98M
Short Ratio i2.695.43
Short % of Float i1.12%2.60%
Shares Outstanding i2.47B538.80M
Float Shares i2.47B537.62M
% Held by Insiders i0.06%0.22%
% Held by Institutions i81.44%85.36%
% Held by Public i18.50%14.42%

Dividend Analysis & Yield Comparison: Merck & Co., Inc. vs Amgen Inc.

MetricMRKAMGN
Last 12-Month Dividend i$3.32$12.18
Last 12-Month Dividend Yield i2.91%3.30%
3-Year Avg Annual Dividend i$3.16$9.98
3-Year Avg Dividend Yield i0.77%0.77%
3-Year Total Dividends i$9.48$29.95
Ex-Dividend DateMar 16, 2026May 15, 2026